Wang, X., Sun, L., Liu, Z., Xing, L., Zhu, Y., Xu, W., . . . Jiang, S. (2023). An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen. Taylor & Francis Group.
Chicago Style (17th ed.) CitationWang, Xinling, Lujia Sun, Zezhong Liu, Lixiao Xing, Yun Zhu, Wei Xu, Shuai Xia, Lu Lu, and Shibo Jiang. An Engineered Recombinant Protein Containing Three Structural Domains in SARS-CoV-2 S2 Protein Has Potential to Act as a Pan-human Coronavirus Entry Inhibitor or Vaccine Antigen. Taylor & Francis Group, 2023.
MLA (9th ed.) CitationWang, Xinling, et al. An Engineered Recombinant Protein Containing Three Structural Domains in SARS-CoV-2 S2 Protein Has Potential to Act as a Pan-human Coronavirus Entry Inhibitor or Vaccine Antigen. Taylor & Francis Group, 2023.